Abstracts tagged "rheumatoid arthritis"

Abstract Number: L09 • ACR Convergence 2023
Efficacy and Safety of LNK01001 in Chinese Patients with Moderate to Severe Active Rheumatoid Arthritis with an Inadequate Response to Conventional Synthetic DMARDs: 24-week Results from a Phase 2 Trial
Chanyuan Wu¹, Xuebin Wang², Jiankang Hu³, Xiaofei Shi⁴, Xiaoxia Wang⁵, Xuan Zhang⁶, Ju Liu⁷, Hui Rao⁸, Jianhong Zhao⁹, Rong Du¹⁰, Zhenyu Jiang¹¹, Huaxiang liu¹², Lin Liu¹³, Shengyun Liu¹⁴, Changhao Xie¹⁵, Xiangping Liao¹⁶, Lie Dai¹⁷, Zhiduo Hou¹⁸, Jingchun Jin¹⁹, Tianwang Li²⁰, Deqian Meng²¹, Yongfu Wang²², Jian Wu²³, Jieruo Gu²⁴, Wei Wei²⁵, Yu Zhuang²⁶, Kuanting Wang²⁷, Rong Zhang²⁸, Xiao Zhang²⁹, Huaping Wei³⁰, Zhao-Kui Wan³¹, Jun Wang³¹, Michael Vazquez³², Henry Wu³³ and Xiaofeng Zeng¹, ¹Peking Union Medical College Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing, China, ²Binzhou Medical University Hospital, Binzhou, China, ³Pingxiang People's Hospital, Pingxiang, China, ⁴The 1st Affiliated Hospital of He'nan University, Luoyang, China, ⁵Second Hospital of Shanxi Medical University, Taiyuan, China, ⁶Beijing Hospital, Beijing, China, ⁷Jiujiang No. 1 People's Hospital, Jiujiang, China, ⁸Hunan Provincial People's Hospital, Changsha, China, ⁹Jining First People's Hospital, Jining, China, ¹⁰Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China, ¹¹First Affiliated Hospital of Jilin University, Changchun, China, ¹²Qilu Hospital of Shandong University, Jinan, China, ¹³Central Hospital of Xuzhou City, Xuzhou, China, ¹⁴The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China, ¹⁵The First Affiliated Hospital of Bengbu Medical College, Bengbu, China, ¹⁶Chenzhou First People's Hospital, Binzhou, China, ¹⁷Sun Yat-Sen Memorial Hospital, Guangzhou, China, ¹⁸Shantou University Medical College No.1 Affiliated Hospital, Shantou, China, ¹⁹Yanbian University Affiliated Hospital, Yanbian, China, ²⁰guangdong second provincial general hospital, Guangzhou, China, ²¹Huai'an First People's Hospital, Huaian, China, ²²The First Affiliated Hospital of Baotou Medical College, Baotou, China, ²³The First Affiliated Hospital of Soochow University, Suzhou, China, ²⁴The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China, ²⁵Tianjin Medical University General Hospital, Tianjin, China, ²⁶Huizhou Central People's Hospital, Huizhou, China, ²⁷Peking University Shougang Hospital, Beijing, China, ²⁸The First Hospital of China Medial University, Shenyang, China, ²⁹Guangdong Provincial People's Hospital, Guangzhou, China, ³⁰Lynk Pharmaceuticals Co., Ltd., Hangzhou, China, ³¹Lynk Pharma, Hangzhou, China, ³²Lynk Pharma, Saint Louis, MO, ³³Lynk Pharma, Nanjing, China
Background/Purpose: LNK01001 is a selective oral JAK1 inhibitor in clinical development for treating autoimmune and inflammatory diseases, including rheumatoid arthritis (RA). Here, we report the…
Abstract Number: L20 • ACR Convergence 2023
Telitacicept, a Human Recombinant Fusion Protein Targeting and Neutralizing B Lymphocyte Stimulator (BlyS) and a Proliferation-Inducing Ligand (APRIL), in Rheumatoid Arthritis (RA) Patients with an Inadequate Response to Methotrexate (MTX): A Randomized, Double-Blind, Phase 3 Study
Li Wang¹, Dong Xu², Jianmin Fang³, Qing Zuraw⁴ and Fengchun Zhang¹, ¹Peking Union Medical College Hospital, Beijing, China, ²Peking Union Medical College Hospital, Dong Cheng District, China, ³RemeGen Co, Ltd., Yantai, China, ⁴RemeGen Biosciences, Inc., San Francisco, CA
Background/Purpose: Telitacicept is a recombinant fusion protein targeting and neutralizing BLyS and APRIL. This phase 3, randomized, double-blind study evaluated the efficacy and safety of…
Abstract Number: 0011 • ACR Convergence 2023
Clock Gene Bmal1 Promotes Transcriptional Activity of NF-κB to Regulate Production of Inflammatory Mediators in RA-FLS
Hikari Tsukamoto¹, Kenta Kaneshiro², Kohsuke Yoshida¹, Koji Tateishi³, Yasuhiro Terashima³, Nao Shibanuma⁴, Yoshitada Sakai⁵ and Akira Hashiramoto¹, ¹Kobe University Graduate School of Health Sciences, Kobe, Japan, ²Kobe University Graduate School of Health Sciences, Osaka, Japan, ³Kohnan Kakogawa Hospital, Kakogawa, Japan, ⁴Kobe Kaisei Hospital, Kobe, Japan, ⁵Kobe University Graduate School of Medicine, Kobe, Japan
Background/Purpose: Rheumatoid arthritis (RA), an autoimmune polyarthritis characterized by 'tumor-like' proliferation of RA fibroblast-like synovial cells (RA-FLS), has characteristic symptoms such as "morning stiffness of…
Abstract Number: 0073 • ACR Convergence 2023
PD-1hi Cells Are Highly Present in the Rheumatoid Joint, and Express Regulatory Capacities
Sofie Rask¹, Christian Andersen², Malene Hvid¹, Kim Ravnskjær², Bent Deleuran¹ and Stinne Greisen³, ¹Aarhus University, Aarhus, Denmark, ²University of Southern Denmark, Odense, Denmark, ³Aarhus University/Aarhus University Hospital, Aarhus, Denmark
Background/Purpose: Programmed death 1 (PD-1) is an immune checkpoint receptor expressed by activated T cells, and of major importance in maintaining peripheral tolerance. Expression of…
Abstract Number: 0174 • ACR Convergence 2023
Evaluation of Healthcare Utilization in Members with Rheumatoid Arthritis, Psoriatic Arthritis, and Systemic Lupus Erythematosus
Jean Park, W. Cliff Rutter, Elisea Avalos-Reyes, Chen Liu, Will Cavers, Dorothea Verbrugge and Kjel Johnson, CVS Health, Woonsocket, RI
Background/Purpose: Healthcare utilization is increasing among patients with rheumatic diseases. While several studies have assessed healthcare utilization in rheumatoid arthritis (RA) patients, few studies have…
Abstract Number: 0380 • ACR Convergence 2023
Use of Digital Health Tools to Evaluate Change in Clinical and Patient-Reported Outcomes Among Patients with Rheumatoid Arthritis Initiating Treatment with a JAKi or TNFi
W. Benjamin Nowell¹, Cassie Clinton², Fenglong Xie², Yuji Su³, Laura Stradford¹, David Curtis⁴, Patrick Zueger⁵, Pankaj Patel⁶, Kelly Gavigan⁷, Shilpa Venkatachalam⁸, Esteban Rivera⁹ and Jeffrey R. Curtis³, ¹Global Healthy Living Foundation, Nyack, NY, ²University of Alabama at Birmingham, Birmingham, AL, ³University of Alabama at Birmingham and Illumination Health, Birmingham, AL, ⁴Global Healthy Living Foundation, San Francisco, CA, ⁵AbbVie, Inc., Mettawa, IL, ⁶AbbVie, Inc., North Chicago, IL, ⁷Global Healthy Living Foundation, Upper Nyack, NY, ⁸Global Healthy Living Foundation, New York, NY, ⁹Global Healthy Living Foundation, Long Island City, NY
Background/Purpose: Although the use of patient-reported outcome (PRO) data has grown more common in the care of people with rheumatoid arthritis (RA), the utility of…
Abstract Number: 0396 • ACR Convergence 2023
Hydroxychloroquine Is Associated with a Decreased Risk of Non-alcoholic Fatty Liver Disease in Patients with Rheumatoid Arthritis: A Population-based, Cohort Study
Hsin-Hua Chen¹ and DER-YUAN CHEN², ¹Taichung Veterans General Hospital, Taichung, Taiwan, ²Center of Rheumatology, China Medical University Hospital, Taichung, Taiwan
Background/Purpose: Rheumatoid arthritis (RA) is a systemic autoimmune inflammatory disease characterized by chronic destructive arthritis and extra-articular involvement. Prior studies showed patients with RA had…
Abstract Number: 0413 • ACR Convergence 2023
Transcriptomic Analysis of Peripheral Blood Mononuclear Cells Reveals Pain and Inflammation Specific Alterations in Difficult-to-treat Rheumatoid Arthritis
Lilla Gunkl-Tóth¹, Gábor Sütő², Gábor Kumánovics³, József Kun⁴, Péter Urbán⁵, Attila Gyenesei⁵, Panna Királyhidi⁶, Georg Schett⁷, György Nagy⁸ and Zsuzsanna Helyes⁹, ¹Department of Pharmacology and Pharmacotherapy, University of Pécs, Hungary; Eötvös Loránd Research Network, University of Pécs, Chronic Pain Research Group, Budapest, Hungary, ²Second Department of Medicine and Nephrology-Diabetes Centre, University of Pécs, Pécs, Hungary, ³Department of Rheumatology and Immunology, Medical School, University of Pécs, Pécs, Hungary, ⁴Department of Pharmacology and Pharmacotherapy, Medical School, University of Pécs, Pécs, Hungary; Bioinformatics Research Group, Genomics and Bioinformatics Core Facility, Szentágothai Research Centre, University of Pécs, Budapest, Hungary, ⁵Bioinformatics Research Group, Genomics and Bioinformatics Core Facility, Szentágothai Research Centre, University of Pécs, Pécs, Hungary, Pécs, Hungary, ⁶Department of Genetics, Cell- and Immunobiology, Semmelweis University School of Medicine, Budapest, Hungary, ⁷Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany, ⁸Department of Rheumatology and Clinical Immunology, Semmelweis University School of Medicine; Department of Genetics, Cell and Immunobiology, Semmelweis University, Budapest, Hungary; Heart and Vascular Centre, Semmelweis University, Budapest, Hungary, ⁹Department of Pharmacology and Pharmacotherapy, Medical School, University of Pécs, Pécs, Hungary; Eötvös Loránd Research Network, University of Pécs, Chronic Pain Research Group, Pécs, Hungary; National Laboratory for Drug Research and Development, Pécs, Hungary
Background/Purpose: Despite novel treatment strategies in rheumatoid arthritis (RA), approximately 20-30% of patients remain symptomatic. The EULAR definition of difficult-to-treat (D2T) RA has recently been…
Abstract Number: 0430 • ACR Convergence 2023
A Multicenter, Real-world Clinical Data Study of the Use of JAK Kinase Inhibitors in a Large Cohort of Patients with Rheumatoid Arthritis
Maria Lopez-Lasanta¹, Helena Borrell¹, Meritxell Salles Lizarzaburu², Virginia Ruiz-Esquide³, Daniel Roig⁴, Annika Nack⁵, Carolina Pérez⁶, Julia Bernardez⁷, Andrea García⁸, Joana Rovira⁹, Andrea Cuervo¹⁰, Marta Valls¹¹, Carmen Garcia¹², Sonia Minguez¹³, Rosa Morla¹⁴, Paula Estrada⁴, Melania Martinez¹⁵, Conxita Pitarch¹⁶, Noemi Busquets¹⁷, Hye Park¹⁸, Jose A Gomez-Puerta¹⁹, Susana Holgado²⁰, Nuria Montala²¹, Raimon Sanmarti³, Lourdes Mateo²⁰, Cesar Diaz²², Hector Corominas²³ and Georgina Salvador⁷, ¹Hospital Universitari Vall d'Hebron, Rheumatology, Barcelona, Spain, ²C. H. de Manresa - Fundació Althaia, Barcelona, Spain, ³Hospital Clinic, Rheumatology, Barcelona, Spain, ⁴Hospital Moisses Broggi, Rheumatology, Barcelona, Spain, ⁵Department of Rheumatology, Hospital Universitari Germans Trias i Pujol, Barcelona, Spain, ⁶Hospital del Mar-Parc de Salut Mar, Rheumatology, Barcelona, Spain, ⁷Hospital Mutua Terrassa, Rheumatology, Barcelona, Spain, ⁸Hospital Sant Pau-Dos de Maig, Rheumatology, Barcelona, Spain, ⁹Hospital de Mollet, Barcelona, Spain, ¹⁰Hospital Granollers, Rheumatology, Barcelona, Spain, ¹¹Hospital Josep Trueta, Rheumatology, Girona, Spain, ¹²Hospital de Terrassa, Rheumatology, Barcelona, Spain, ¹³Fundació Althaia, Manresa, Spain, ¹⁴Hospital Clinic, Rheumatology, Barcelona, Barcelona, Spain, ¹⁵Hospital Germans Trias i Pujol, Rheumatology, Barcelona, Spain, ¹⁶Hospital Universitari de la Santa Creu i Sant Pau, Rheumatology, Barcelona, Spain, ¹⁷HOSP. GENERAL DE GRANOLLERS, GRANOLLERS, Spain, ¹⁸Hospital Universitari Sant Pau, Rheumatology, Barcelona, Spain, ¹⁹Department of Rheumatology, Hospital Clinic of Barcelona, Barcelona, Spain, ²⁰Hospital Universitari Germans Trias i Pujol, Rheumatology, Barcelona, Spain, ²¹Hospital Santa Maria, Rheumatology, Lleida, Spain, ²²Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, ²³Hospital Universitario Sant Pau, Rheumatology, Barcelona, Spain
Background/Purpose: The Janus Kinase inhibitors (JAKi) drugs are approved for use in adults with moderate to severe rheumatoid arthritis (RA). Real-world studies are necessary as…
Abstract Number: 0447 • ACR Convergence 2023
Glucocorticoid Use in Rheumatoid Arthritis Patients Initiating Biological or Targeted Synthetic Disease Modifying Anti-rheumatic Drugs (b/tsDMARDs) in Real Life: Data from BIOBADASER
Lucia Otero-Valera¹, Jose María Alvaro-Gracias², Jerusalem Calvo³, Cristina Campos⁴, Alicia Garcia Dorta⁵, Fernando Sánchez-Alonso⁶ and Isabel Castrejon⁷, ¹Spanish Society of Rheumatology, Madrid, Spain, ²Hospital General Universitario Gregorio Marañon, Madrid, Spain, ³Reina Sofia University Hospital, Córdoba, Spain, ⁴Rheumatology Unit, Hospital General Universitario de Valencia, Valencia, Spain, ⁵Rheumatology Unit, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, ⁶Fundación Española de Reumatología, Madrid, Spain, ⁷Hospital Universitario Gregorio Marañón, Madrid, Spain
Background/Purpose: Glucocorticoids are frequently used as bridging therapy for rheumatoid arthritis (RA) patients starting conventional synthetic DMARDs. Both EULAR and ACR guidelines (1,2), recommend to…
Abstract Number: 0476 • ACR Convergence 2023
Factors Associated with the Need for Assisted Reproductive Therapies in a Spanish Cohort of Patients with Rheumatic Diseases
Antía García-Fernández¹, Fernando Rengifo-García¹, Raquel Senosiain-Echarte¹, Miguel álvaro-Navidad¹, Miguel A Gonzalez-Gay² and Juan A Martínez-López¹, ¹Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain, ²IDIVAL and School of Medicine, UC, Santander; Department of Rheumatology, IIS-Fundación Jiménez Díaz, Madrid, Santander, Spain
Background/Purpose: Patients with rheumatic diseases (RMD) have a lower pregnancy rate, with infertility being one of the main causes. The rate of assisted reproductive therapies…
Abstract Number: 0771 • ACR Convergence 2023
A Modified Idiopathic Pulmonary Fibrosis-Derived Composite Biomarker Score Is Associated with Interstitial Lung Disease Among U.S. Veterans with Rheumatoid Arthritis
Brent Luedders¹, Dana Ascherman², Daniel Kass³, Joshua Baker⁴, Michael Duryee¹, Yangyuna Yang¹, Punyasha Roul¹, K Wysham⁵, Paul Monach⁶, Andreas Reimold⁷, Gail Kerr⁸, Gary Kunkel⁹, Grant Cannon¹⁰, Jill Poole¹, Geoffrey Thiele¹, Ted R Mikuls¹¹ and Bryant England¹, ¹University of Nebraska Medical Center, Omaha, NE, ²University of Pittsburgh, Pittsburgh, PA, ³University of Pittsburgh School of Medicine, Pittsburgh, PA, ⁴University of Pennsylvania, Philadelphia, PA, ⁵VA Puget Sound/University of Washington, Seattle, WA, ⁶VA Boston Healthcare System, Boston, MA, ⁷University of Texas Southwestern Medical Center, Dallas, TX, ⁸Washington DC VAMC/Georgetown and Howard Universities, Washington, DC, ⁹University of Utah, Salt Lake City, UT, ¹⁰University of Utah and Salt Lake City VA, Salt Lake City, UT, ¹¹Division of Rheumatology and Immunology, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Based on the overlap in peripheral blood biomarkers associated with rheumatoid arthritis interstitial lung disease (RA-ILD) and idiopathic pulmonary fibrosis (IPF), a composite biomarker…
Abstract Number: 0823 • ACR Convergence 2023
Sleep Disturbance Predicts Pain Interference in Patients with Early Rheumatoid Arthritis in a Prospective Real-World Cohort
Burcu Aydemir¹, Orit Schieir², Marie-France Valois³, Lutfiyya Muhammad¹, Jing Song¹, dorothy Dunlop¹, Susan Bartlett⁴, Louis Bessette⁵, Gilles Boire⁶, Glen Hazelwood⁷, Carol Hitchon⁸, Edward Keystone⁹, Janet Pope¹⁰, Carter Thorne¹¹, Diane Tin¹², Vivian Bykerk¹³, Yvonne Lee¹⁴ and Canadian Early Arthritis Cohort (CATCH) Investigators¹⁵, ¹Northwestern University Feinberg School of Medicine, Chicago, IL, ²McGill University, Montréal, QC, Canada, ³McGill University, Pointe-Claire, QC, Canada, ⁴McGill University, Montreal, QC, Canada, ⁵Centre de l'Ostéoporose et de Rhumatologie de Québec, Quebec City, QC, Canada, ⁶Université de Sherbrooke, Sherbrooke, QC, Canada, ⁷University of Calgary, Calgary, AB, Canada, ⁸University of Manitoba, Manitoba, MB, Canada, ⁹Keystone Consulting Enterprises Inc., Toronto, ON, Canada, ¹⁰University of Western Ontario, London, ON, Canada, ¹¹Southlake Regional Health Centre, Newmarket, ON, Canada, ¹²Newmarket Rheumatology Consultants, Newmarket, ON, Canada, ¹³Department of Rheumatology, Hospital for Special Surgery, New York, NY, ¹⁴Northwestern University, Chicago, IL, ¹⁵CATCH, Winnipeg, MB, Canada
Background/Purpose: Despite taking strong immunosuppressive medications to control inflammation, many patients with rheumatoid arthritis (RA) continue to experience moderate to severe pain that does not…
Abstract Number: 0981 • ACR Convergence 2023
Time Trends in Overall Infection Risk in Patients with Inflammatory Arthritides Treated with Tumor Necrosis Factor Inhibitors
Aron Hjalti Bjornsson¹, Telma Thrastardottir², Bjorn Gudbjornsson³ and Thorvardur Love⁴, ¹Landspitali University Hospital and the University of Iceland, Reykjavík, Iceland, ²University of Iceland, Reykjavik, Iceland, ³Centre for Rheumatology Research, University Hospital, Reykjavik, Iceland, ⁴Landspitali University Hospital and the University of Iceland, Reykjavik, Iceland
Background/Purpose: Infections are a known complication of disease-modifying therapy in rheumatic patients but have also been associated with the diseases being treated. Biosimilars have increased…
Abstract Number: 1033 • ACR Convergence 2023
The Detection of Subclinical Joint Inflammation by Thermal and Ultrasound Imaging at the Metacarpophalangeal Joints in Patients with Rheumatoid Arthritis
York Kiat Tan¹ and Gek Hsiang Lim², ¹Department of Rheumatology and Immunology, Singapore General Hospital, Singapore, Singapore, ²Health Services Research Unit, Singapore General Hospital, Singapore, Singapore
Background/Purpose: While magnetic resonance imaging and ultrasound (US) imaging have been shown to be useful in the detection of subclinical joint inflammation in rheumatoid arthritis…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].